{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-22-000030","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.414739+00:00","generated_at":"2026-06-21T19:46:45.048124+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS revises REGAL trial SAP; observed OS ~2-fold longer, enrollment to 125-140","bullets":["Pooled blinded data shows overall survival ~2-fold longer than original protocol assumption; interim analysis reduced to 60 events, final to 80.","Enrollment target increased from 116 to 125-140 patients; partner 3D Medicines to add ~20 patients from China.","Milestone payments from 3DMed expected in H1 2023; potential for earlier China market entry if REGAL meets endpoints.","Q3 2022 net loss $7.0M ($0.34 per share); cash and equivalents $21.3M as of Sep 30, 2022.","Company hosting virtual investor event on REGAL update at 8:30 a.m. ET today."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-22-000030","json":"https://secwatch.observer/filing/0001390478-22-000030.json","markdown":"https://secwatch.observer/filing/0001390478-22-000030.md","text":"https://secwatch.observer/filing/0001390478-22-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/0001390478-22-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/sls-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:46:45.048124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5316f2c5faa5b03780a6eac534ee0c1c54ace739","claim":"SELLAS Life Sciences Group, Inc. reported quarter ended September 30, 2022 results: net income Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34.","evidence_excerpt":"On November 14, 2022, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047822000030/0001390478-22-000030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}